Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
Posts Tagged ‘IPO’
RTP Wrapup 10/30
Friday, October 30, 2009, 4:24 amA test that assesses Tysabri’s risk of causing potentially deadly side effects could boost demand of the multiple sclerosis drug, GlaxoSmithKline is not ready to talk about efforts to develop a successor to best selling asthma medicine Advair and RTI International researchers will try to make biomass “oil.”
Next: A crucial decision
Thursday, September 3, 2009, 8:23 amThis is the last part. Continued from part 2.
Next: A crucial decision
Tuesday, July 28, 2009, 9:14 amThis is the last part. Continued from part 2.
Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
